在中度和重度的COPD患者中,纳米库尔库调节了Th17细胞的反应
Amirhossein Mardi1, Samaneh Abdolmohammadi-Vahid2, Sarvin Alizadeh Sadeghi3
1Department of Immunology, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
Heliyon
|May 13, 2024
概括
在中度和重度慢性阻塞性肺病 (COPD) 患者中,纳米库尔库显著降低了T助手17 (Th17) 细胞频率和相关的炎症性细胞因子. 这表明纳米库尔库可能作为COPD治疗的免疫调节剂.
科学领域:
- 免疫学 免疫学 免疫学
- 肺部病理学 肺部病理学
- 纳米医学是一种纳米医学.
背景情况:
- 慢性阻塞性肺病 (COPD) 涉及呼吸道炎症和气流阻塞,通常与吸烟有关.
- 辅助性T细胞17 (Th17) 通过释放促炎性细胞因子,加剧高炎症和疾病进展,促进COPD的发病.
研究的目的:
- 评估纳米库尔库明在调节COPD患者Th17细胞频率和相关反应中的治疗潜力.
- 评估纳米库尔库明对与Th17相关的基因表达和中度和重度COPD中的细胞因子水平的影响.
主要方法:
- 在一项随机对照试验中包括20名严重和20名中度COPD患者.
- 通过流细胞计,实时PCR和ELISA评估Th17细胞频率,基因表达 (RORγt,IL-17,IL-21,IL-23,GM-CSF) 和血清细胞因子水平.
- 纳米黄素治疗与安慰剂的比较,与治疗前和后的测量.
主要成果:
- 与安慰剂相比,纳米库尔库明治疗导致中度和重度COPD患者的Th17细胞频率显著降低.
- 在纳米库尔库明组中观察到,Th17相关因子的mRNA表达和Th17细胞因子的分泌量大幅下降.
- 与治疗前水平相比,这些标记物在纳米库尔库明组的治疗后显著较低.
结论:
- 在COPD患者中,纳米库尔库有效降低了Th17细胞数量及其相关的炎症性细胞因子.
- 纳米库尔库显示出作为一种免疫调节剂的潜力,可以缓解中度至重度COPD的炎症.
相关概念视频
01:26COPD: Management Using Bronchodilators and Corticosteroids
197
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
197
01:24T Cell Types and Functions
1.0K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.0K
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
115
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
115
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
277
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
277
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
2.8K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
2.8K
01:17Drugs Used in Lower Respiratory Disorders: Overview
424
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
424